Literature DB >> 19367165

Oseltamivir and abnormal behaviors: true or not?

Takashi Yorifuji1, Etsuji Suzuki, Toshihide Tsuda.   

Abstract

Oseltamivir is a neuraminidase inhibitor that inhibits influenza virus proliferation, and is used as an antiviral drug against influenza A and B viruses. Recently, concerns have been raised about hallucinations, delirium, and abnormal activity after administration of oseltamivir for treatment of infection with influenza virus. A large epidemiologic study was conducted in Japan in the winter of 2006-2007 to assess the relationship between oseltamivir intake and adverse behaviors, and an interim report was released on 10 July 2008. In the report, the research group concluded that no positive associations were detected between oseltamivir intake and abnormal behaviors. However, the analytic method used in the study was flawed. A correct analysis (based on person-time) shows a rate ratio of 1.57 (95% confidence interval = 1.34-1.83). This example clearly illustrates the importance of person-time in the analysis of cohort studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19367165     DOI: 10.1097/EDE.0b013e3181a3d3f6

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  10 in total

1.  Clinical and epidemiological characteristics of patients with influenza A (H1N1) 2009 attended to at the emergency room of a children's hospital.

Authors:  Esther Lera; Núria T Wörner; Mónica Sancosmed; Anna Fàbregas; Alejandro Casquero; Susana Melendo; Mar Miserachs; Teresa Tórtola; Astrid Borrego; Magda Campins; Fernando Moraga; Concepció Figueras; Rocío Cebrián
Journal:  Eur J Pediatr       Date:  2011-01-28       Impact factor: 3.183

Review 2.  Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic.

Authors:  Larry E Davis
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

3.  The Relationship Between Oseltamivir and Suicide in Pediatric Patients.

Authors:  Rachel Harrington; Sruthi Adimadhyam; Todd A Lee; Glen T Schumock; James W Antoon
Journal:  Ann Fam Med       Date:  2018-03       Impact factor: 5.166

Review 4.  Antivirals for influenza: strategies for use in pediatrics.

Authors:  Steven M Smith; John G Gums
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

5.  Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.

Authors:  Takuro Okada; Masayuki Hashiguchi; Satoko Hori
Journal:  Int J Clin Pharm       Date:  2022-09-26

6.  Oseltamivir (tamiflu) induced depressive episode in a female adolescent.

Authors:  Sungho Chung; Yoo Sook Joung
Journal:  Psychiatry Investig       Date:  2010-11-11       Impact factor: 2.505

7.  Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database.

Authors:  Hisashi Urushihara; Yuko Doi; Masaru Arai; Toshiyuki Matsunaga; Yosuke Fujii; Naoko Iino; Takashi Kawamura; Koji Kawakami
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

Review 8.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

9.  Impacts of rapid flu clinic services at an emergency department during the pandemic flu season.

Authors:  Hsin-I Shih; Tzong-Shiann Ho; Chia-Ming Chang; Hsiang-Chin Hsu; Shih-Min Wang; Ching-Chuan Liu; Wen-Chien Ko; Yi-Hui Wu; Yen-Ling Chiu; Bor-Shyang Sheu; Chih-Hsien Chi
Journal:  Am J Infect Control       Date:  2011-07-20       Impact factor: 2.918

Review 10.  The mechanisms of sudden-onset type adverse reactions to oseltamivir.

Authors:  R Hama; C L Bennett
Journal:  Acta Neurol Scand       Date:  2016-06-30       Impact factor: 3.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.